BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

, Reuters - 8:13 AM ET 4/3/2025 default

April 3 (Reuters) - Aldeyra Therapeutics Inc ( ALDX ):

* ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE

* ALDEYRA THERAPEUTICS INC ( ALDX ) -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025

* ALDEYRA THERAPEUTICS INC ( ALDX ) -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025

* ALDEYRA THERAPEUTICS ( ALDX ) - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS Source text: Further company coverage: ;))

(c) Reuters 2025. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.